Influence of MMP on Brain AVM Hemorrhage
Primary Purpose
Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Doxycycline or Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Arteriovenous Malformations
Eligibility Criteria
Inclusion Criteria:
- 13 years or older
- Female patients of child bearing age using barrier-type birth control
- Creatinine no greater than 2.0 mg/di
- Alanine aminotransferase (ALT) no greater than 2 times upper limit of normal
- WBC count at least 3,800/mm3
- BMI within 50% of normal
Exclusion Criteria:
- Allergy to tetracycline
- Unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days
- Female patients of child-bearing age not using effective birth control (barrier)
- History of vestibular disease (except benign positional vertigo)
- History of noncompliance with treatment or other experimental protocols
- Patients taking other antibiotics
- History of systemic lupus erythematosis
- Patients who are immunocompromised Patients with clinically significant hepatic dysfunction
Sites / Locations
- University of California
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Doxycycline
Placebo
Arm Description
Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
Outcomes
Primary Outcome Measures
Our primary aim is to perform a pilot study to document the effect of doxycycline therapy to decrease MMP expression in the vascular malformation tissue.
Secondary Outcome Measures
Our secondary aims are: (1) To explore whether plasma MMP-9 levels can be used as a marker for MMP-9 inhibition in the vascular malformation lesional tissue
Full Information
NCT ID
NCT00783523
First Posted
October 30, 2008
Last Updated
August 6, 2013
Sponsor
University of California, San Francisco
1. Study Identification
Unique Protocol Identification Number
NCT00783523
Brief Title
Influence of MMP on Brain AVM Hemorrhage
Official Title
Influence of Matrix Metalloproteinase on Brain Arteriovenous Malformation Hemorrhage
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
March 2008 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Brain vascular malformations, including arteriovenous malformations (AVM), cavernous malformations (CVM) and aneurysms, are a source of life-threatening risk of intracranial hemorrhage. The etiology and pathogenesis are unknown. There is no medical therapy presently available. Prevention of spontaneous intracerebral hemorrhage (ICH) is the primary reason to treat brain vascular malformations. The goal of this study is to: begin pilot studies to lay the groundwork for future clinical trials to develop medical therapy to decrease ICH risk.
Matrix metalloproteinases (MMPs) regulate the extracellular matrix in association with various hemorrhagic brain disorders. MMP-9 has been most consistently associated with vascular wall instability and hemorrhagic brain disorders. Doxycycline, a non-specific MMP inhibitor, may enhance vascular stability, thus reducing the risk of spontaneous hemorrhage in brain vascular malformations by decreasing MMP-9 activity.
Detailed Description
Doses will be randomized by the Pharmacy Department at UCSF for Doxycycline 100 mg/BID and Placebo BID. These will be prepared in blister-packs.
Depending on enrollment/surgery date, patients will take medication either one to two weeks before surgery. Patients will be assigned to a treatment group according to a random table.
Each patient will be initially provided with a 1 or 2-week supply of drug in blister packs. The patient will take the final dose of study drug on the morning of surgery.
Baseline labs will be obtained and then again at time of surgery along with a piece of surgical tissue.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Doxycycline
Arm Type
Active Comparator
Arm Description
Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
Intervention Type
Drug
Intervention Name(s)
Doxycycline or Placebo
Other Intervention Name(s)
Doxycycline, Placebo
Intervention Description
Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
Primary Outcome Measure Information:
Title
Our primary aim is to perform a pilot study to document the effect of doxycycline therapy to decrease MMP expression in the vascular malformation tissue.
Time Frame
1 to 2-week pre-operative
Secondary Outcome Measure Information:
Title
Our secondary aims are: (1) To explore whether plasma MMP-9 levels can be used as a marker for MMP-9 inhibition in the vascular malformation lesional tissue
Time Frame
1 to 2-week pre operative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
13 years or older
Female patients of child bearing age using barrier-type birth control
Creatinine no greater than 2.0 mg/di
Alanine aminotransferase (ALT) no greater than 2 times upper limit of normal
WBC count at least 3,800/mm3
BMI within 50% of normal
Exclusion Criteria:
Allergy to tetracycline
Unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days
Female patients of child-bearing age not using effective birth control (barrier)
History of vestibular disease (except benign positional vertigo)
History of noncompliance with treatment or other experimental protocols
Patients taking other antibiotics
History of systemic lupus erythematosis
Patients who are immunocompromised Patients with clinically significant hepatic dysfunction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chanhung Lee, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Influence of MMP on Brain AVM Hemorrhage
We'll reach out to this number within 24 hrs